Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Tenofovir-related tubule damage characterized by Fanconi syndrome, renal insufficiency and nephrogenic diabetes insipidus has been reported in the adult HIV-infected population. To our knowledge there has been no reported case of such complications in the pediatric population. We report the case of a 12-year-old perinatally HIV-infected African-American girl who developed nephrogenic diabetes insipidus, renal insufficiency and Fanconi-like syndrome while taking tenofovir (Viread) in combination with lopinavir-ritonavir (Kaletra) and didanosine (Videx).
Hussain
Sabiha
S
Pediatric Infectious Diseases and Immunology, University of Florida, Jacksonville, FL, USA.
Khayat
Abeer
A
Tolaymat
Asad
A
Rathore
Mobeen H
MH
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives; D019380:Anti-HIV Agents / Q000009:adverse effects*; D002648:Child; D018500:Diabetes Insipidus, Nephrogenic / Q000139:chemically induced; D016049:Didanosine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005198:Fanconi Syndrome / Q000139:chemically induced; D005260:Female; D006678:HIV / Q000472:pathogenicity*; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000139:chemically induced*; D061466:Lopinavir; D063065:Organophosphonates / Q000009:adverse effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011744:Pyrimidinones / Q000009:adverse effects; D019438:Ritonavir / Q000009:adverse effects; D000068698:Tenofovir
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D011744:Pyrimidinones; D061466:Lopinavir; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine; D019438:Ritonavir